• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6/5/25 8:11:08 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email
    6-K 1 press_release_june_5_202.htm 6-K 6-K

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June, 2025.

     

    Commission File Number: 001-39530

     

     

    ImmunoPrecise Antibodies Ltd.

    Industrious 823 Congress Ave Suite 300 Austin, Texas 78701

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒

    Form 40-F ☐

     

     


     

     

    EXHIBIT INDEX

     

     

    Exhibit

    Description

    99.1

     

    Press Release dated June 5, 2025

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

     

    IMMUNOPRECISE ANTIBODIES LTD.

    Date: June 5, 2025

     

     

     

     

     

    By:

    /s/ Jennifer Bath

     

    Name:

    Jennifer Bath

     

    Title:

    President and Chief Executive Officer

     

     


    Get the next $IPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

      H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

      12/2/22 8:15:24 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

      Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:31:59 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

      The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:28:32 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care